Results 11 to 20 of about 24,384 (185)
Regulatory Mechanisms in Biosystems, 2019 The activity of antioxidant protection enzymes in the blood serum and colon mucosa in rats was studied under the conditions of 28-days administration of omeprazole on its own and omeprazole together with multiprobiotics "Symbiter" and "Apibact ...
S. V. Pylypenko, A. A. Koval
doaj +1 more source
Journal of Veterinary Internal Medicine, 2023 Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) in horses after discontinuation of omeprazole.
Bethanie Clark +6 more
doaj +1 more source
Frontiers in Plant Science, 2019 Omeprazole is a selective proton pump inhibitor in humans that inhibits the H+/K+-ATPase of gastric parietal cells. Omeprazole has been recently shown to act as a plant growth regulator and enhancer of salt stress tolerance.
Michael James Van Oosten +7 more
doaj +1 more source
Molecular pathways driving omeprazole nephrotoxicity
Redox Biology, 2020 Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux disease, has been associated to chronic kidney disease and acute interstitial nephritis. However, whether omeprazole is toxic to renal cells is unknown. Omeprazole
Miguel Fontecha-Barriuso +8 more
doaj +1 more source
Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. [PDF]
PLoS ONE, 2013 The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter.
Annamaria Tonazzi +2 more
doaj +1 more source
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
PLoS ONE, 2011 BackgroundOmeprazole has recently been described as a modulator of tumour chemoresistance, although its underlying molecular mechanisms remain controversial.
Andrej Udelnow +9 more
doaj +1 more source
Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils. [PDF]
Pediatr Allergy ImmunolAbstract Background Eosinophilic esophagitis (EoE) is a chronic allergic disorder driven by type 2 inflammation, characterized by eosinophilic infiltration and esophageal epithelial abnormalities, including barrier dysfunction, basal cell hyperplasia, epithelial thickening, and loss of differentiation.
Gautam R +6 more
europepmc +2 more sources
Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
Pharmaceutical Biology, 2019 Context: Omeprazole and astragaloside IV (AS-IV) are widely used for the treatment of gastric ulcers in China clinics. Objective: This study investigates the effects of AS-IV on the pharmacokinetics of omeprazole in rats.
Wei Liu, Guozhi Liu, Jing Liu
doaj +1 more source
Journal of Pharmacy & Pharmaceutical Sciences, 2007 Purpose. To investigate the effect of diabetes mellitus induced by alloxan (DMIA) or streptozotocin (DMIS) on the pharmacokinetics of omeprazole in rats.
Dae Young Lee +3 more
doaj +1 more source
Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans. [PDF]
Clin Pharmacol TherGrapefruit juice is a well‐established inhibitor of cytochrome P450 (CYP) 3A4, but its effects on other CYP enzymes or organic anion transporting polypeptides (OATPs) are not fully characterized in humans. Recently, lingonberry powder was shown to induce murine CYP enzymes. We investigated the effects of lingonberry powder and grapefruit juice on seven
Aurinsalo L +7 more
europepmc +2 more sources